GSK shingles vaccine shown 82% effective 11 years after vaccination
https://seekingalpha.com/news/4090624-gsk-shingles-vaccine-shown-highly-effective-11-years-after-vaccination?source=feed_sector_healthcare
Apr 17, 2024 - GSK (GSK) said studies showed that its top-selling shingles vaccine, Shingrix, had an 82% efficacy rate 11 years after vaccination in people aged 50 and older. Read more here.
0
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
https://www.zacks.com/stock/news/2257993/biotech-stock-roundup-regn-sage-nmra-down-on-updates-itci-gains-on-study-success?cid=CS-ZC-FT-analyst_blog|stock_roundup-2257993
Apr 18, 2024 - Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
0
Why the Market Dipped But GSK (GSK) Gained Today
https://www.zacks.com/stock/news/2258816/why-the-market-dipped-but-gsk-gsk-gained-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2258816
Apr 19, 2024 - In the latest trading session, GSK (GSK) closed at $39.75, marking a +1.22% move from the previous day.
0
GSK Gears Up for Q1 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2260559/gsk-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2260559
Apr 23, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
0
Pages: 1
Page 1